B
BioTheranostics
Extensive research generates high-complexity molecular tools that help physicians execute more informed treatment decisions
About BioTheranostics
Biotheranostics, headquartered in San Diego, CA, specializes in genomic testing for oncology, focusing on breast and metastatic cancers. The company offers proprietary genomic assays, such as the Breast Cancer Index, which is the only test recognized by both the ASCO and NCCN Clinical Practice Guidelines. These tests help predict the benefit of extended endocrine therapy in hormone receptor-positive, early-stage breast cancer, and identify tumor types and subtypes in metastatic cancer patients with unclear diagnoses. Acquired by Hologic in February 2021, Biotheranostics continues to support personalized disease management in oncology. The company primarily serves oncologists and healthcare providers, operating within the precision medicine market. Biotheranostics generates revenue through the sale of its genomic tests, which are used to guide treatment decisions and improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1996
- Headquarters
- San Diego, United States
- Employees
- 97
- Open positions
- None listed
- Dealroom signal
- 32.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Risk Management, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, medical testing, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Feb 2021 | $230M | $230M | Hologic | ↗ |
| GROWTH EQUITY VC✓Equity / VC | Jan 2016 | $32M | — | Evidity Health Capital · MVM Life Science Partners · HealthQuest Capital | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for BioTheranostics is 240 monthly website visits, down 36.8% over the last three months. BioTheranostics's team declined 16.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Evidity Health Capital
MVM Life Science Partners
HealthQuest Capital
Other known investors2 additional known investors
BioMérieux
Hologic
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioTheranostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioTheranostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.